ARVN has been the subject of a number of other research reports. Morgan Stanley reduced their target price on Arvinas from $63.00 to $57.00 and set an equal weight rating for the company in a report on Friday, November 11th. Barclays initiated coverage on Arvinas in a report on Friday, September 9th. They issued an overweight rating and a $90.00 target price for the company. Citigroup reduced their target price on Arvinas from $103.00 to $88.00 in a report on Thursday, August 18th. HC Wainwright reduced their target price on Arvinas from $135.00 to $90.00 and set a buy rating for the company in a report on Friday, August 5th. Finally, SVB Leerink reduced their target price on Arvinas from $89.00 to $74.00 and set an outperform rating for the company in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, Arvinas currently has a consensus rating of Moderate Buy and an average price target of $80.80.
Arvinas Stock Performance
Shares of NASDAQ:ARVN opened at $40.70 on Tuesday. Arvinas has a one year low of $34.90 and a one year high of $83.40. The stock has a fifty day moving average of $45.72 and a 200-day moving average of $45.88. The company has a market capitalization of $2.17 billion, a PE ratio of -8.55 and a beta of 1.89.
Hedge Funds Weigh In On Arvinas
Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.
- Get a free copy of the StockNews.com research report on Arvinas (ARVN)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.